Literature DB >> 20186103

Inherited cancer syndromes in children and young adults.

John A D'Orazio1.   

Abstract

Geneticists estimate that 5% to 10% of all cancers diagnosed in the pediatric age range occur in children born with a genetic mutation that directly increases their lifetime risk for neoplasia. However, despite the fact that only a fraction of cancers in children occur as a result of an identified inherited predisposition, characterizing genetic mutations responsible for increased cancer risk in such syndromes has resulted in a profound understanding of relevant molecular pathways involved in carcinogenesis and/or resistance to neoplasia. Importantly, because most cancer predisposition syndromes result in an increased risk of a small number of defined malignancies, personalized prophylactic surveillance and preventive measures can be implemented in affected patients. Lastly, many of the same genetic targets identified from cancer-prone families are mechanistically involved in the majority of sporadic cancers in adults and children, thereby underscoring the clinical relevance of knowledge gained from these defined syndromes and introducing novel therapeutic opportunities to the broader oncologic community. This review highlights the clinical and genetic features of many of the known constitutional genetic syndromes that predispose to malignancy in children and young adults.

Entities:  

Mesh:

Year:  2010        PMID: 20186103     DOI: 10.1097/MPH.0b013e3181ced34c

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  11 in total

1.  Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Authors:  Daria V Babushok; Monica Bessler; Timothy S Olson
Journal:  Leuk Lymphoma       Date:  2015-12-23

2.  A concurrent episode of two neoplasms in a toddler-age child.

Authors:  Muaz A Alrazzak; Jenny Zablahalabi; Baraa Alrazzak; Guillermo De Angulo
Journal:  Avicenna J Med       Date:  2014-04

Review 3.  Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach.

Authors:  Lester Dr Thompson
Journal:  Mod Pathol       Date:  2017-01       Impact factor: 7.842

Review 4.  Familial myelodysplastic syndromes: a review of the literature.

Authors:  Elena Liew; Carolyn Owen
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

Review 5.  The DNA damage response: making it safe to play with knives.

Authors:  Alberto Ciccia; Stephen J Elledge
Journal:  Mol Cell       Date:  2010-10-22       Impact factor: 17.970

6.  Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.

Authors:  Carolyn Fein Levy; Lubaina S Presswala; Alana Slomovic; Jessica Stiefel; Rifka Schulman-Rosenbaum
Journal:  Pediatr Blood Cancer       Date:  2020-11-23       Impact factor: 3.838

Review 7.  Retroperitoneal liposarcoma: current insights in diagnosis and treatment.

Authors:  Lucas E Matthyssens; David Creytens; Wim P Ceelen
Journal:  Front Surg       Date:  2015-02-10

Review 8.  Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8.

Authors:  Carolyn C Jackson; Mark A Dickson; Mahan Sadjadi; Antoine Gessain; Laurent Abel; Emmanuelle Jouanguy; Jean-Laurent Casanova
Journal:  Pediatr Blood Cancer       Date:  2015-10-15       Impact factor: 3.167

9.  Incidence, Risk Factors, and Mortality Associated With Second Malignant Neoplasms Among Survivors of Adolescent and Young Adult Cancer.

Authors:  Chun Chao; Smita Bhatia; Lanfang Xu; Kimberly L Cannavale; F Lennie Wong; Po-Yin Samuel Huang; Robert Cooper; Saro H Armenian
Journal:  JAMA Netw Open       Date:  2019-06-05

10.  A new mutL homolog 1 c.1896+5G>A germline mutation detected in a Lynch syndrome-associated lung and gastric double primary cancer patient.

Authors:  Xuyuan Chen; Xiang Li; Hongsen Liang; Lichun Wei; Qiang Cui; Ming Yao; Xu Wu
Journal:  Mol Genet Genomic Med       Date:  2019-06-17       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.